Update shared on10 Aug 2025
Fair value Decreased 7.69%The reduction in Krishna Institute of Medical Sciences' price target reflects a decline in its future P/E ratio, suggesting lower expected earnings multiples despite stable revenue growth forecasts, resulting in the fair value estimate decreasing from ₹820.62 to ₹757.54.
What's in the News
- Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for Q1 ended June 30, 2025, and other matters.
- Special/Extraordinary Shareholders Meeting to consider re-appointment of Prameela Rani Yalamanchili as independent director for a second five-year term via postal ballot.
- Expected Q1 2026 earnings release date is August 7, 2025.
Valuation Changes
Summary of Valuation Changes for Krishna Institute of Medical Sciences
- The Consensus Analyst Price Target has fallen from ₹820.62 to ₹757.54.
- The Future P/E for Krishna Institute of Medical Sciences has fallen from 52.88x to 48.14x.
- The Consensus Revenue Growth forecasts for Krishna Institute of Medical Sciences remained effectively unchanged, moving only marginally from 25.1% per annum to 25.5% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.